Chemoprevention of asbestos-linked cancers: A systematic review

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 1005-1013

  Neri, Monica ^a   Ugolini, Donatella ^b,c   Boccia, Stefania ^a,d   Canessa, Pier Aldo ^e   Cesario, Alfredo ^a,d   Leoncini, Giacomo ^c   Mutti, Luciano ^f   Bonassi, Stefano ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e Ospedale San Bartolomeo   (Italy)

^f Local Health Unit 11   (Italy)

Author keywords

Asbestos; Chemoprevention; Lung neoplasms; Mesothelioma; Review

Indexed keywords

ANTIOXIDANT; ASBESTOS; BETA CAROTENE; BIOLOGICAL MARKER; PLACEBO; RETINOL;

CANCER RISK; CHEMICAL CARCINOGENESIS; CHEMICALLY INDUCED DISORDER; CHEMOPROPHYLAXIS; ENVIRONMENTAL EXPOSURE; FOLLOW UP; HEALTH SURVEY; HUMAN; LUNG CANCER; MALIGNANT MESOTHELIOMA; MEDLINE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ASBESTOS; CARCINOGENS; CHEMOPREVENTION; HUMANS; NEOPLASMS;

EID: 84858758492     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Doll R and Peto J: Asbestos. Effects on Health of Exposure to Asbestos. Review for the Health and Safety Commission. Sudbury, UK, HSE Books, 1985.
2. Murray HM: Report of the Departmental Committee on Compensation for Industrial Disease. London, UK, Her Majesty's Stationery Office, 1907.
3. International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. Vol. 14. Asbestos. Lyon, France, IARC. 1977.
4. Environmental ProtectionAgency: Airborne Asbestos Health Assessment Update. EPA/6000/8-84/003E, Washington, DC, USA, EPA, 1986.
5. British Geological Survey. World Mineral Production 2004-08. Nottingham, UK, British Geological Survey, 2010.
6. Frost G, Harding AH, Darnton A, McElvenny D and Morgan D: Occupational exposure to asbestos and mortality among asbestos removal workers: a Poisson regression analysis. Br J Cancer 99: 822-829, 2008.
7. Bourdès V, Boffetta P and Pisani P: Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Eur J Epidemiol 16: 411-417, 2000.
8. Bruno C, Comba P and Zona A: Adverse health effects of fluoroedenitic fibers: epidemiological evidence and public health priorities. Ann NY Acad Sci 1076: 778-783, 2006. (Pubitemid 44955307)
9. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M and Pass HI: A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 7: 147-154, 2007. (Pubitemid 46160990)
10. Marinaccio A, Scarselli A, Binazzi A, Mastrantonio M, Ferrante P and Iavicoli S: Magnitude of asbestos-related lung cancer mortality in Italy. Br J Cancer 99: 173-175, 2008. (Pubitemid 351920243)
11. Lin RT, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D and Kameda T: Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 369: 844-849, 2007. (Pubitemid 46365901)
12. Nishikawa K, Takahashi K, Karjalainen A, Wen CP, Furuya S, Hoshuyama T, Todoroki M, Kiyomoto Y, Wilson D, Higashi T, Ohtaki M, Pan G and Wagner G: Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: a global assessment. Environ Health Perspect 116: 1675-1680, 2008.
13. Artieda L, Beloqui A and Lezaun M: Cohort of asbestos exposed workers. Navarre (Spain) 1999-2004. An Sist Sanit Navar 28: 335-344, 2005 (in Spanish). (Pubitemid 43187107)
14. Dell DM, Bohnker BK, Muller JG, Philippi AF, Litow FK, Rudolph WG, Hernandez JE and Hiland DA: Navy Asbestos Medical Surveillance Program 1990-1999: demographic features and trends in abnormal radiographic findings. Mil Med 171: 717-722, 2006. (Pubitemid 44204880)
15. Dement J, Welch L, Haile E and Myers D: Mortality among sheet metal workers participating in a medical screening program. Am J Ind Med 52: 603-613, 2009.
16. Roberts HC, Patsios DA, Paul NS, DePerrot M, Teel W, Bayanati H, Shepherd F and Johnston MR: Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol 4: 620-628, 2009.
17. Mastrangelo G, Ballarin MN, Bellini E, Bicciato F, Zannol F, Gioffrè F, Zedde A, Tessadri G, Fedeli U, Valentini F, Scoizzato L, Marangi G and Lange JH: Asbestos exposure and benign asbestos diseases in 772 formerly exposed workers: doseresponse relationships. Am J Ind Med 52: 596-602, 2009.
18. Das M, Mühlenbruch G, Mahnken AH, Hering KG, Sirbu H and Zschiesche W: Asbestos Surveillance Program Aachen (ASPA): initial results from baseline screening for lung cancer in asbestos-exposed high-risk individuals using low-dose multidetector-row CT. Eur Radiol 17: 1193-1199, 2007. (Pubitemid 46691948)
19. Ray M and Kindler HL: Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 136: 888-896, 2009.
20. Merler E, Buiatti E and Vainio H: Surveillance and intervention studies on respiratory cancers in asbestos-exposed workers. Scand J Work Environ Health 23: 83-92, 1997. (Pubitemid 27214005)
21. Greenwald P: Cancer chemoprevention. Br Med J 324: 714-718, 2002.
22. Wattenberg LW: Chemoprevention of cancer. Cancer Res 45: 1-8, 1985.
23. Hecht SS, Kassie F and Hatsukami DK: Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nature Rev 9: 476-488, 2009.
24. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S and Hammar S: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150-1155, 1996. (Pubitemid 26137973)
25. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, Haapakoski J, Rautalahti M, Hartman AM and Palmgren J: Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 62: 1427S-1430S, 1995.
26. McLarty JW, Holiday DB, Girard WM, Yanagihara RH, Kummet TD and Greenberg SD: Beta-Carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 62(suppl): 1431S-1438S, 1995.
27. Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens FL Jr, Omenn GS, Valanis B and Williams JH Jr.: The beta-carotene and retinol efficacy trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping β-carotene and retinol supplements. J Natl Cancer Inst 96: 1743-1750, 2004. (Pubitemid 39654568)
28. Subramanian S: Baseline Characteristics and Predictors of Occurrence of Mesothelioma among Asbestos-Exposed Occupations in the Beta-Carotene and Retinol Efficacy Trial (CARET). Thesis for the degree of Master of Public Health, University of Washington, 2006.
29. De Klerk, Musk AW, Ambrosini GL, Eccles JL, Hansen J, Olsen N, Watts VL, Lund HG, Pang SC, Beilby J and Hobbs MS: Vitamin A and cancer prevention I: comparison of the effects of retinol and β-carotene. Int J Cancer 75: 362-367, 1998.
30. Musk AW, de Klerk NH, Ambrosini GL, Eccles JL, Hansen J, Olsen NJ, Watts VL, Lund HG, Pang SC, Beilby J and Hobbs MS: Vitamin A and cancer prevention I: observations in workers previously exposed to asbestos at Wittenoom, Western Australia. Int J Cancer 75: 355-361, 1998. (Pubitemid 28100035)
31. Pluygers E, Baldewyns P, Minette P, Beauduin M, Gourdin P and Robinet P: Biomarker assessment in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: rationale and practical implementations. Eur J Cancer Prev 1: 129-138, 1992.
32. Catalano A, Graciotti L, Rinaldi L, Raffaelli G, Rodilossi S and Betta P: Preclinical evaluation of the nonsteroidalanti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer 109: 322-328, 2004. (Pubitemid 38252758)
33. Apostolou S, Klein JO, Mitsuuchi Y, Shetler JN, Poulikakos PI and Jhanwar SC: Growth inhibition and induction of apoptosis in mesotelioma cells by selenium and dependence on selenoprotein SEP15 genotype. Oncogene 23: 5032-5040, 2004. (Pubitemid 38938736)
34. Häner K, Henzi T, Pfefferli M, Künzli E, Salicio V and Schwaller B: A bipartite butyrate-responsive element in the human calretinin (CALB2) promoter acts as a repressor in colon carcinoma cells but not in mesothelioma cells. J Cell Biochem 109: 519-531, 2010.
35. Berry G, de Klerk NH, Reid A, Ambrosini GL, Fritschi L, Olsen NJ, Merler E and Musk AW: Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia. Occup Environ Med 61: e14, 2004.
36. Kamp DW and Weitzman SA: The molecular basis of asbestos induced lung injury. Thorax 54: 638-652, 1999. (Pubitemid 29296687)
37. Bonassi S, Znaor A, Ceppi M, Lando C, Chang WP and Holland N: An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 28: 625-631, 2007. (Pubitemid 46523357)
38. Valavanidis A, Vlachogianni T and Fiotakis C: 8-Hydroxy-2′- deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27: 120-39, 2009.
39. Bolognesi C, Martini F, Tognon M, Filiberti R, Neri M and Perrone E: A molecular epidemiology case-control study on pleural malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 14: 1741-1746, 2005. (Pubitemid 40995089)
40. El-Zein RA, Schabath MB, Etzel CJ, Lopez MS, Franklin JD and Spitz MR: Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk. Cancer Res 66: 6449-6456, 2006.
41. Dostert C, Petrilli, V,Van Bruggen R, Steele C, Mossman BT and Tschopp J: Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320: 674-677, 2008. (Pubitemid 351928351)
42. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
43. Tomasetti M, Amati M, Santarelli L, Alleva R and Neuzil J: Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol 2: 190-206, 2009.